RNA Horizons 2024

Program

Wednesday, September 25, 2024

RNA systems biology

09:35 – 09:55

Manuel Irimia, Centre for Genomic Regulation, Barcelona, Spain

10:00 – 10:20

Katharina Höfer, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany

10:50 – 11:10

Mary A. O’Connell, Central European Institute of Technology (CEITEC), Brno, Czech Republic

11:15 – 11:35

Martin Akerman, Envisagenics Inc. New York, USA

Poster Teasers

11:40 – 12:00

The Interplay of Transcription and Splicing

13:00 – 13:20

Maria Carmo-Fonseca, Institute for Molecular Medicine (IMM), University of Lisbon, Portugal

miRNA-Based Logic Circuits Encoded on Self-Amplifying RNA for Highly Specific Cancer Cell Classification

13:25 - 13:45

Ron Weiss, Massachusetts Institute of Technology, USA

Development of FTO inhibitors for mRNA stabilization to treat AML cancer

13:50 - 14:10

Amir MorRNAble, Ness Ziona, Israel

RNA therapeutics development

14:15-14:20

Opening Remarks:  Rotem Karni, The Institute for Medical Research Israel-CanadaHebrew University- Hadassah Medical School, Israel

Keynote Lecture | Antisense Therapy for Diffuse Midline Glioma

14:20 - 15:00

Adrian R. Krainer, Cold Spring Harbor Laboratory, New York, USA

REM-422, a small molecule that reprograms RNA processing to target MYB-driven hematological and solid cancers

16:00 - 16:20

Silvia Buonamici, Remix Therapeutics, Watertown, MA, USA

Oral splicing-regulation therapy for genetic diseases and cancer

16:25 - 16:45

Masatoshi Hagiwara, MD & PhD, Professor & Chairman, Graduate School of Medicine, Department of Drug Discovery Medicine, Kyoto University, Japan

Neutrophil-specific mRNA delivery - shooting at a moving target​

16:50 - 17:10

Zvika Granot, Faculty of Medicine, Hebrew University, Jerusalem, Israel

Panel Discussion: Turning Science into Solutions: The Power of the CanceRNA Consortium

17:15 - 18:45

Tamar Raz, CEO, Hadasit Medical Research Services and Development

TBD

17:40-18:00

Thursday, September 26, 2024

RNA therapeutics development (cont.)

Splice-switching Antisense Oligonucleotide Drug Discovery for Rare Neurodegenerative Diseases

08:50 - 09:10

Michelle L. Hastings, University of Michigan, Ann Arbor, MI, USA

Modulating mRNA stability for genetic diseases and cancer therapy

09:15 - 09:35

Rotem Karni, The Institute for Medical Research Israel-Canada, Hebrew University- Hadassah Medical School, Israel

RNA splicing in cancer

Building specificity of anti-tumor splicing inhibitors targeting SF3B1.

10:50 – 11:10

Juan Valcarcel, Centre for Genomic Regulation, Barcelona, Spain

11:15 – 11:35

Florian Heyd, Free University of Berlin, Germany

Alternative splicing of immune receptors as a regulatory mechanism

11:40 – 12:00

Michal Lotem, Hadassah Hebrew University Medical Center, Jerusalem, Israel

12:00 – 12:20

Niels Schaft, University of Erlangen, Erlangen, Germany

Poster Session

12:55 - 13:30

A-to-I RNA editing in cancer

15:50 – 16:10

Erez Levanon, Bar Ilan University, Ramat Gan, Israel 

Friday, September 27, 2024

CanceRNA Internal Meeting | RNA therapeutics